This category page covers biotechnology and pharmaceutical companies developing ion channel modulators for Alzheimer's disease (AD). Ion channels represent a promising therapeutic target for neurodegeneration, with companies targeting:
- Potassium channels (Kv7/KCNQ family) — neuronal hyperexcitability and neuroprotection
- Calcium channels (L-type, T-type, P/Q-type) — calcium dysregulation and excitotoxicity
- Sodium channels — neuronal firing patterns and excitotoxicity
These mechanisms address key pathological features of AD including calcium dysregulation, neuroinflammation, synaptic dysfunction, and progressive neuronal loss.
The Kv7 (KCNQ) family of potassium channels regulates neuronal excitability by stabilizing the resting membrane potential. In AD, Kv7 channels are implicated in:
- Amyloid-beta toxicity: Kv7 activation protects neurons from Aβ-induced cytotoxicity
- Synaptic function: Kv7 modulators improve synaptic plasticity and memory
- Hyperexcitability: Restoring normal firing patterns reduces seizure-like activity in AD models
- Neuroprotection: Kv7 activation reduces oxidative stress and mitochondrial dysfunction
Calcium dysregulation is a hallmark of AD, with excessive calcium influx leading to:
- Excitotoxicity: Overactivation of NMDA receptors and downstream cell death pathways
- Tau phosphorylation: Calcium-dependent kinases promote NFT formation
- Neuroinflammation: Calcium-activated microglia release pro-inflammatory cytokines
- Mitochondrial dysfunction: Calcium overload impairs energy production
Voltage-gated sodium channels contribute to AD pathophysiology through:
- Neuronal hyperexcitability: Increased firing patterns and seizure activity
- Dendritic spine loss: Sodium dysregulation affects synaptic structure
- Glutamate toxicity: Dysregulated sodium channels exacerbate excitotoxicity
- Network oscillations: Altered sodium channel function disrupts brain rhythms
- Headquarters: New Haven, Connecticut, USA
- Ticker: NYSE: BHVN (acquired by Pfizer 2023)
- Focus: Kv7.2/7.3 (KCNQ2/3) potassium channel activators
- Lead Programs:
- Troriluzole (BHVN-4151): Kv7 activator in Phase 2 for AD
- BHVN-7010: Next-generation Kv7 activator, Phase 1
- Pipeline:
| Drug |
Mechanism |
Indication |
Stage |
| Troriluzole |
Kv7.2/7.3 activator |
Alzheimer's disease |
Phase 2 |
| BHVN-7010 |
Kv7 activator |
Alzheimer's disease |
Phase 1 |
| Troriluzole |
Kv7.2/7.3 activator |
ALS |
Phase 3 |
- Technology: Acquired Kv7 platform from Bristol-Myers Squibb (2018)
- Relevance: Oral bioavailability, established safety, BBB penetration
- See: Biohaven
- Headquarters: Boston, Massachusetts, USA
- Ticker: NASDAQ: CREV
- Focus: Kv7.2/7.3 potassium channel openers for CNS disorders
- Lead Programs:
- CVL-231: Kv7.2/7.3 opener, Phase 2 for AD
- Pipeline:
| Drug |
Mechanism |
Indication |
Stage |
| CVL-231 |
Kv7.2/7.3 opener |
Alzheimer's disease |
Phase 2 |
| CVL-634 |
M4 positive allosteric modulator |
Schizophrenia |
Phase 1 |
- Technology: Formerly part of Pfizer, spun out 2020
- See: Cerevel Therapeutics
- Headquarters: San Diego, California, USA
- Focus: Kv7.2/7.3 modulators for neurodegenerative diseases
- Lead Programs: Kv7 targeting compounds in preclinical development
- Technology: Novel chemistry platform for CNS ion channel modulators
- See: Quralis
- Headquarters: Cambridge, Massachusetts, USA
- Focus: Lysosomal potassium channel (TMEM175) agonists
- Lead Programs: TMEM175 modulators for PD and AD
- Relevance: TMEM175 regulates lysosomal pH and autophagy; dysfunction linked to neurodegeneration
- Mechanism: Small molecule agonists of TMEM175 lysosomal potassium channel
- See: Lysoway Therapeutics
- Headquarters: Tokyo, Japan
- Ticker: TYO: 4568
- Focus: α2δ subunit calcium channel modulators
- Marketed Products:
- Tarlige (mirogabalin): α2δ calcium channel blocker approved for neuropathic pain
- Pipeline:
| Drug |
Target |
Indication |
Stage |
| Mirogabalin |
α2δ calcium channel |
Neuropathic pain |
Approved |
| DA-9801 |
Novel |
Alzheimer's disease |
Preclinical |
| DS-7891 |
Mitochondrial function |
Parkinson's disease |
Phase 1 |
- Technology: Established calcium channel modulation platform
- Relevance: Mirogabalin's mechanism is applicable to calcium dysregulation in AD
- See: Daiichi Sankyo
- Headquarters: Tokyo, Japan
- Founded: 2016
- Focus: Structure-based drug design for CNS disorders, calcium channel modulators
- Lead Programs:
- ACC-004: T-type and L-type calcium channel modulator for PD/AD
- Pipeline:
| Drug |
Target |
Indication |
Stage |
| ACC-001 |
Novel kinase |
Alzheimer's disease |
Lead optimization |
| ACC-004 |
T-type/L-type calcium channels |
Alzheimer's disease |
Discovery |
| ACC-002 |
LRRK2 |
Parkinson's disease |
Discovery |
- Technology: Proprietary structure-based drug design platform with cryo-EM and computational modeling
- Scientific Rationale: T-type channels (Cav3.1, Cav3.2) contribute to neuronal hyperexcitability; L-type channels (Cav1.3) show altered function in aging neurons
- See: Accerise Inc.
- Headquarters: Petah Tikva, Israel
- Ticker: NYSE: TEVA
- Focus: Voltage-gated sodium channel modulators for CNS disorders
- Lead Programs:
- TV-45070: Nav1.7/1.8 sodium channel blocker for PD and pain
- Pipeline:
| Drug |
Target |
Indication |
Stage |
| TV-45070 |
Nav1.7/1.8 |
Parkinson's disease |
Phase 2 |
- Technology: Sodium channel blockade reduces neuronal firing patterns associated with movement disorders
- Relevance: May address motor symptoms and dyskinesias beyond dopaminergic approaches
- See: Teva Pharmaceuticals
- Headquarters: Boston, Massachusetts, USA
- Ticker: VRTX
- Focus: Non-addictive pain treatments via sodium channel inhibitors
- Technology: NaV1.8 inhibitors provide analgesia without CNS effects
- Pipeline: Sodium channel programs in development for pain, potential AD applications
- See: Vertex
- Headquarters: Aachen, Germany
- Focus: Sodium channel blockers for pain and CNS disorders
- Lead Programs: NaV1.7 and NaV1.8 selective inhibitors
- Partnerships: Novartis (early-stage pain programs), AstraZeneca (CNS disorders including AD)
- See: Grünenthal
- Headquarters: Osaka, Japan
- Ticker: TYO: 4507
- Focus: Selective sodium channel blockade
- Lead Programs: S-010887 targeting NaV1.7 for pain
- Technology: Novel chemical scaffolds for selective sodium channel inhibition
- See: Shionogi
- Headquarters: Heidelberg, Germany
- Focus: Sodium channel modulation and neuroprotection
- Technology: Novel sodium channel modulators with neuroprotective properties
- See: Axxonis
¶ Competitive Landscape
| Company |
Primary Mechanism |
AD Focus |
Key Asset |
Stage |
| Biohaven |
Kv7 potassium activator |
Yes |
Troriluzole |
Phase 2 |
| Cerevel |
Kv7 potassium opener |
Yes |
CVL-231 |
Phase 2 |
| Daiichi Sankyo |
α2δ calcium channel |
Yes |
Mirogabalin (repurposing) |
Approved |
| Accerise |
T-type/L-type calcium |
Yes |
ACC-004 |
Discovery |
| Lysoway |
Lysosomal K+ channel |
Emerging |
TMEM175 agonists |
Preclinical |
| Teva |
NaV1.7/1.8 |
Emerging |
TV-45070 |
Phase 2 |
| Vertex |
NaV1.8 inhibitor |
Emerging |
Pipeline |
Discovery |
| Grünenthal |
NaV1.7/1.8 |
Emerging |
Pipeline |
Discovery |
- Neuroprotection: Potassium and calcium channel modulators protect neurons from amyloid-beta and tau toxicity
- Synaptic preservation: Restoring normal ion channel function preserves synaptic connections
- Excitotoxicity reduction: Calcium and sodium channel blockade reduces glutamate-induced cell death
- Network normalization: Ion channel modulation restores normal neuronal firing patterns
- Biomarker strategies: EEG, calcium imaging, and synaptic markers for patient selection
- Combination approaches: Ion channel modulators combined with amyloid/tau-targeting therapies
- Genetic stratification: Targeting patients with ion channel genetic variants
- Delivery methods: Oral, intranasal, and transdermal formulations for optimal brain penetration